JP2009502800A5 - - Google Patents

Download PDF

Info

Publication number
JP2009502800A5
JP2009502800A5 JP2008522947A JP2008522947A JP2009502800A5 JP 2009502800 A5 JP2009502800 A5 JP 2009502800A5 JP 2008522947 A JP2008522947 A JP 2008522947A JP 2008522947 A JP2008522947 A JP 2008522947A JP 2009502800 A5 JP2009502800 A5 JP 2009502800A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
polyethylene glycol
polypeptide
seq
encoded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008522947A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009502800A (ja
JP4987001B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/028106 external-priority patent/WO2007013944A2/en
Publication of JP2009502800A publication Critical patent/JP2009502800A/ja
Publication of JP2009502800A5 publication Critical patent/JP2009502800A5/ja
Application granted granted Critical
Publication of JP4987001B2 publication Critical patent/JP4987001B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008522947A 2005-07-20 2006-07-20 癌および自己免疫障害を処置するためのｉｌ２８およびｉｌ２９の短縮型システイン変異体の使用法 Active JP4987001B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70095105P 2005-07-20 2005-07-20
US60/700,951 2005-07-20
US77126006P 2006-02-08 2006-02-08
US60/771,260 2006-02-08
PCT/US2006/028106 WO2007013944A2 (en) 2005-07-20 2006-07-20 Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders

Publications (3)

Publication Number Publication Date
JP2009502800A JP2009502800A (ja) 2009-01-29
JP2009502800A5 true JP2009502800A5 (https=) 2009-09-03
JP4987001B2 JP4987001B2 (ja) 2012-07-25

Family

ID=37683787

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008522947A Active JP4987001B2 (ja) 2005-07-20 2006-07-20 癌および自己免疫障害を処置するためのｉｌ２８およびｉｌ２９の短縮型システイン変異体の使用法

Country Status (7)

Country Link
US (5) US20070020227A1 (https=)
EP (1) EP1909821A2 (https=)
JP (1) JP4987001B2 (https=)
AU (1) AU2006272937A1 (https=)
CA (1) CA2616004A1 (https=)
IL (1) IL188357A0 (https=)
WO (1) WO2007013944A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60135393D1 (de) * 2000-06-30 2008-09-25 Zymogenetics Inc Allelische Variante des Interferon-ähnlichen Proteins Zcyto21
US7038032B2 (en) 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
EP2251352A1 (en) * 2003-08-07 2010-11-17 ZymoGenetics, L.L.C. Homogeneous preparations of IL-28 and IL-29
EP1912668A2 (en) * 2005-07-20 2008-04-23 ZymoGenetics, Inc. Il28 and il29 truncated cysteine mutants and antiviral methods of using same
AU2006272937A1 (en) * 2005-07-20 2007-02-01 Bristol-Myers Squibb Company Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders
CA2625208A1 (en) 2005-10-04 2007-04-12 Zymogenetics, Inc. Production and purification of il-29
JP5083898B2 (ja) * 2007-07-11 2012-11-28 日本特殊陶業株式会社 アンモニアガスセンサ
JP2009115776A (ja) * 2007-07-11 2009-05-28 Ngk Spark Plug Co Ltd アンモニアガスセンサ
AU2009255994B2 (en) * 2008-06-05 2014-07-17 Bristol-Myers Squibb Company Use of pegylated Type III Interferons for the treatment of hepatitis C
US20100316608A1 (en) * 2009-06-15 2010-12-16 Vijayaprakash Suppiah Method of Determining A Response To Treatment With Immunomodulatory Composition
FR2975185A1 (fr) * 2011-05-12 2012-11-16 Univ Claude Bernard Lyon Procede de determination in vitro de la presence d'une sclerose en plaques
CN104045704B (zh) * 2013-03-11 2016-08-10 中国医学科学院基础医学研究所 PEG化重组人IFN-λ1、其制备方法和用途
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
CN103923209B (zh) * 2014-05-13 2016-06-22 北京凯因科技股份有限公司 一种Lambda干扰素突变体及聚乙二醇衍生物
CN105085658B (zh) * 2014-05-14 2019-12-24 杭州先为达生物科技有限公司 一种白细胞介素29突变体及聚乙二醇衍生物
DE102015001902A1 (de) * 2015-02-18 2016-08-18 Continental Reifen Deutschland Gmbh Verfahren zur Verbesserung der Haftung zwischen einem Verstärkungselement und einem elastomeren Matrixmaterial
WO2016172342A1 (en) 2015-04-21 2016-10-27 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
JP7674628B2 (ja) 2016-02-19 2025-05-12 イーアイティー・ファーマ・インコーポレイテッド インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置
MX2019003744A (es) * 2016-09-30 2019-10-30 Univ Leland Stanford Junior Interferones de variante tipo iii y sintecinas.
WO2021119749A1 (en) * 2019-12-20 2021-06-24 The Council Of The Queensland Institute Of Medical Research Treatment of gastrointestinal disease
GB202003595D0 (en) * 2020-03-12 2020-04-29 Ilc Therapeutics Ltd Compositions and methods relating to the treatment of diseases
KR102226826B1 (ko) * 2020-08-06 2021-03-11 주식회사 휴벳바이오 버피 코트 시료에 사용하기 위한 췌장암 진단용 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8308534A1 (es) 1980-01-08 1983-09-01 Biogen Nv Un metodo de producir un polipeptido que exhibe actividad inmunologica o biologica del interferon de leucocitos humanos.
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US6468776B1 (en) * 2000-03-03 2002-10-22 Zymogenetics, Inc. Human serine protease
US6822082B2 (en) * 2000-06-30 2004-11-23 Zymogenetics, Inc. Polynucleotides for mammalian secreted protein, Z1055G2P
DE60135393D1 (de) * 2000-06-30 2008-09-25 Zymogenetics Inc Allelische Variante des Interferon-ähnlichen Proteins Zcyto21
ATE549347T1 (de) 2000-09-08 2012-03-15 Schering Corp Gene von säugetiere, und damit verbundene reagentien, methoden
EP1942187B1 (en) * 2001-04-20 2010-09-22 ZymoGenetics, L.L.C. Cytokine protein family
US7038032B2 (en) * 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
WO2002092762A2 (en) * 2001-05-10 2002-11-21 Immunex Corporation Cytokine polypeptides
WO2003066002A2 (en) * 2002-02-08 2003-08-14 University Of Medicine And Dentistry Of New Jersey IFN-a/b-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION
CN1659274A (zh) 2002-04-19 2005-08-24 津莫吉尼蒂克斯公司 细胞因子受体
CA2503305A1 (en) * 2002-10-23 2004-05-06 Zymogenetics, Inc. Methods for treating viral infection using il-28 and il-29
EP2251352A1 (en) * 2003-08-07 2010-11-17 ZymoGenetics, L.L.C. Homogeneous preparations of IL-28 and IL-29
JP4896005B2 (ja) 2004-04-02 2012-03-14 ザイモジェネティクス リミテッド ライアビリティ カンパニー Ｉｌ−２８およびｉｌ−２９システイン変異体を用いるウイルス感染を治療するための方法
JP2008508310A (ja) * 2004-07-29 2008-03-21 ザイモジェネティクス， インコーポレイテッド がんおよび自己免疫障害を治療するためのｉｌ−２８およびｉｌ−２９の使用法
CN1305902C (zh) 2004-11-25 2007-03-21 汕头大学医学院 一种人白细胞介素29的生产方法及重组il－29工程菌
EP1912668A2 (en) * 2005-07-20 2008-04-23 ZymoGenetics, Inc. Il28 and il29 truncated cysteine mutants and antiviral methods of using same
AU2006272937A1 (en) * 2005-07-20 2007-02-01 Bristol-Myers Squibb Company Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders
CA2625208A1 (en) * 2005-10-04 2007-04-12 Zymogenetics, Inc. Production and purification of il-29

Similar Documents

Publication Publication Date Title
JP2009502800A5 (https=)
JP2009502803A5 (https=)
JP2008508310A5 (https=)
JP2012255007A5 (https=)
JP2005177500A5 (https=)
JP2010505444A5 (https=)
JP2010534486A5 (https=)
WO2010033220A3 (en) Modified therapeutics peptides, methods of their preparation and use
NZ592250A (en) Modified animal erythropoietin polypeptides and their uses
JP2012532601A5 (https=)
EP2174668A3 (en) Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
JP2009514172A5 (https=)
JP2010522141A5 (https=)
IL202645A (en) A chimeric antibody linked to CD37, its DNA-encoded molecule, a pharmaceutical preparation containing it and its use in the preparation of a drug
JP2012525844A5 (https=)
JP2006006329A5 (https=)
JP2008503230A5 (https=)
JP2012517818A5 (https=)
WO2006132670A3 (en) Auristatins having an aminobenzoic acid unit at the n terminus
JP2005518433A5 (https=)
JP2010529860A5 (https=)
NZ593311A (en) Albumin binding peptide-mediated disease targeting
JP2014513941A5 (https=)
WO2008013948A3 (en) Tyrosine phosphorylation sites
JP2009503174A5 (https=)